196 related articles for article (PubMed ID: 33997936)
1. Differences in lymphoma patients between chimeric antigen receptor T-cell therapy trials and the general population.
Apaydin EA; Richardson AS; Baxi S; Vockley J; Akinniranye O; Larkin J; Motala A; Hempel S
Clin Exp Med; 2022 Feb; 22(1):151-155. PubMed ID: 33997936
[TBL] [Abstract][Full Text] [Related]
2. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
[TBL] [Abstract][Full Text] [Related]
4. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
Sharma P; King GT; Shinde SS; Purev E; Jimeno A
Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
[TBL] [Abstract][Full Text] [Related]
5. CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.
Bluhm J; Kieback E; Marino SF; Oden F; Westermann J; Chmielewski M; Abken H; Uckert W; Höpken UE; Rehm A
Mol Ther; 2018 Aug; 26(8):1906-1920. PubMed ID: 30078440
[TBL] [Abstract][Full Text] [Related]
6. Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.
Hunter BD; Rogalski M; Jacobson CA
Expert Opin Biol Ther; 2019 Nov; 19(11):1157-1164. PubMed ID: 31342797
[No Abstract] [Full Text] [Related]
7. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
[TBL] [Abstract][Full Text] [Related]
8. Toxicity and efficacy of chimeric antigen receptor T-cell therapy in patients with diffuse large B-cell lymphoma above the age of 70 years compared to younger patients - a matched control multicenter cohort study.
Ram R; Grisariu S; Shargian-Alon L; Amit O; Bar-On Y; Stepensky P; Yeshurun M; Avni B; Hagin D; Perry C; Gurion R; Sarid N; Herishanu Y; Gold R; Glait-Santar C; Kay S; Avivi I
Haematologica; 2022 May; 107(5):1111-1118. PubMed ID: 34233446
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Axicabtagene Ciloleucel and Tisagenlecleucel Administration in Lymphoma Patients With Secondary CNS Involvement: A Systematic Review.
Wu X; Zhang X; Xun R; Liu M; Sun Z; Huang J
Front Immunol; 2021; 12():693200. PubMed ID: 34290712
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
Wang N; Meng Y; Wu Y; He J; Liu F
Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
[No Abstract] [Full Text] [Related]
11. The promise of CAR T-cell therapy in aggressive B-cell lymphoma.
Nair R; Neelapu SS
Best Pract Res Clin Haematol; 2018 Sep; 31(3):293-298. PubMed ID: 30213399
[TBL] [Abstract][Full Text] [Related]
12. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
Abramson JS; Lunning M; Palomba ML
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
[TBL] [Abstract][Full Text] [Related]
13. Radiation and Chimeric Antigen Receptor T-cell Therapy in B-cell Non-Hodgkin Lymphomas.
Deshpande A; Rule W; Rosenthal A
Curr Treat Options Oncol; 2022 Jan; 23(1):89-98. PubMed ID: 35167008
[TBL] [Abstract][Full Text] [Related]
14. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
15. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
Cao G; Lei L; Zhu X
Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
[TBL] [Abstract][Full Text] [Related]
16. The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.
Cao JX; Wang H; Gao WJ; You J; Wu LH; Wang ZX
Cytotherapy; 2020 Apr; 22(4):214-226. PubMed ID: 32305113
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the association between bridging therapy and outcomes of chimeric antigen receptor T cell therapy in patients with large B cell lymphoma.
Sun Z; Liu M
Cytotherapy; 2022 Sep; 24(9):940-953. PubMed ID: 35568624
[TBL] [Abstract][Full Text] [Related]
19. Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells.
Karschnia P; Rejeski K; Winkelmann M; Schöberl F; Bücklein VL; Blumenberg V; Schmidt C; Blobner J; von Bergwelt-Baildon M; Tonn JC; Kunz WG; Subklewe M; von Baumgarten L
Neurology; 2022 May; 98(21):884-889. PubMed ID: 35351785
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
